Holen Sie sich die Stockscreener-App
119.81
1.11%
-1.385
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$121.19
Offen:
$121.07
24-Stunden-Volumen:
2.12M
Relative Volume:
0.29
Marktkapitalisierung:
$148.64B
Einnahmen:
$29.05B
Nettoeinkommen (Verlust:
$8.11B
KGV:
18.56
EPS:
6.4563
Netto-Cashflow:
$9.16B
1W Leistung:
-3.28%
1M Leistung:
+0.85%
6M Leistung:
+6.06%
1J Leistung:
+32.30%
1-Tages-Spanne:
$119.05
$122.25
1-Wochen-Bereich:
$119.05
$125.60
52-Wochen-Spanne:
$88.57
$128.70
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
119.81 | 150.36B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
989.19 | 892.86B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
201.17 | 485.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
224.13 | 394.34B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
131.90 | 249.77B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
97.36 | 245.55B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Lombard Odier Asset Management Switzerland SA Raises Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer - Business Wire
Jump Financial LLC Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Three Catalysts Driving Investor Attention Toward Gilead Sciences - AD HOC NEWS
Gilead Sciences, Inc. $GILD Shares Sold by Bank of Nova Scotia - MarketBeat
ASH25: CAR-T Leaders Gilead, J&J Show in Multiple Myeloma; Fulcrum Rises on Sickle Cell Data - BioSpace
WINTON GROUP Ltd Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
ASH: Gilead preps filing for anito-cel on iMMagine-1 data - pharmaphorum
What Does the Market Think About Gilead Sciences Inc? - Benzinga
Gilead Sciences, Inc. $GILD Shares Bought by Natixis - MarketBeat
35,296 Shares in Gilead Sciences, Inc. $GILD Bought by SVB Wealth LLC - MarketBeat
Gilead moves ahead on Chess Hatch project - San Mateo Daily Journal
L2 Asset Management LLC Buys 28,592 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
GILD's Yescarta Shows Promising Results for Lymphoma Patients - GuruFocus
GILD's Kite Unveils Promising CAR T-Cell Therapy Results at ASH Meeting - GuruFocus
ASH: Gilead’s Kite Plots 2026 Launch For Anito-Cel For Multiple Myeloma - Citeline News & Insights
ASH: Anito-cel strengthens best-in-class potential as Gilead's Kite preps for launch - Fierce Biotech
New data from Gilead, Arcellx multiple myeloma CAR-T suggest benefit over rival treatment - statnews.com
Federated Hermes Inc. Sells 1,885,664 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Position Decreased by Brown Advisory Inc. - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Baird Financial Group Inc. - MarketBeat
Why The Narrative Around Gilead Sciences Is Shifting After HIV And Oncology Updates - Yahoo Finance
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition - GlobeNewswire Inc.
First Trust Advisors LP Sells 1,512,069 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Arrowstreet Capital Limited Partnership Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
1832 Asset Management L.P. Makes New $4.69 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Marshall Wace LLP Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Dodge & Cox Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Epoch Investment Partners Inc. Has $95.16 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by CW Advisors LLC - MarketBeat
Amundi Purchases 1,614,355 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Sprint Bioscience (Q3 review)Gilead deal a strong confirmation - marketscreener.com
Redeye: Sprint Bioscience (Q3 review)Gilead deal a strong confirmation - TradingView
Is Gilead Sciences Inc. (GIS) stock good for long term investingJuly 2025 Rallies & Stock Timing and Entry Methods - Newser
Gilead's Seat at the Table of Conversations Centered Around HIV - Gilead Sciences
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know - Yahoo Finance
VestGen Advisors LLC Lowers Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Channing Capital Management LLC Purchases 43,875 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by Guggenheim Capital LLC - MarketBeat
Groupe la Francaise Has $3.92 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Stock Outlook: Mizuho Lifts Target Amid Stronger Biktarvy Timeline - MSN
Gilead (GILD) Valuation After Fresh Buy Rating and Extended Biktarvy Exclusivity Boost Investor Confidence - Yahoo Finance UK
Gilead Sciences, Inc. $GILD Shares Bought by Loomis Sayles & Co. L P - MarketBeat
Invesco Ltd. Buys 3,394,330 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Jeffrey Bluestone Sells 5,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Health Hires: Goodwin Partner Joins Incyte, Gilead GC Exits - Law360
Gilead Sciences (NASDAQ:GILD) CEO Sells $1,265,400.00 in Stock - MarketBeat
Gilead Sciences (NASDAQ:GILD) Director Sells $356,515.50 in Stock - MarketBeat
Gilead Sciences (NASDAQ:GILD) Director Sells $356,670.66 in Stock - MarketBeat
Transcript : Gilead Sciences, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 11 - marketscreener.com
Insider Activity Update: Jeffrey Bluestone Executes Options Exercise, Resulting In $296K At Gilead Sciences - Benzinga
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gilead Sciences Inc-Aktie (GILD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bluestone Jeffrey | Director |
Nov 28 '25 |
Sale |
125.08 |
5,000 |
625,400 |
8,920 |
| Kramer Kelly A. | Director |
Nov 26 '25 |
Option Exercise |
81.00 |
2,806 |
227,286 |
4,145 |
| Kramer Kelly A. | Director |
Nov 28 '25 |
Option Exercise |
81.00 |
2,805 |
227,205 |
4,144 |
| Kramer Kelly A. | Director |
Nov 26 '25 |
Sale |
127.11 |
2,806 |
356,671 |
1,339 |
| Kramer Kelly A. | Director |
Nov 28 '25 |
Sale |
127.10 |
2,805 |
356,516 |
1,339 |
| O'Day Daniel Patrick | Chairman & CEO |
Nov 28 '25 |
Sale |
126.54 |
10,000 |
1,265,444 |
571,203 |
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):